Search

Theracurmin, which contains the curcumin composition, CR-033P, has been demonstrated to be highly bioavailable. To compare the pharmacokinetics of the three compositions, CR-033P, CR-043P using modified starch as an alternative to the dispersant gum ghatti used in the CR-033P, and TS-P1 containing the newly developed amorphous curcumin, a randomized double-blind crossover study (3-way, 3-period) was conducted.A single dose of the curcumin capsules (TS-P1 45 mg, CR-033P 90 mg, and CR-043P 90 mg) was administered to healthy adult participants. Blood sampling was performed 24 hours after capsule administration, and the plasma concentration of total curcumin was determined using high-performance liquid chromatography coupled with tandem mass spectrometry.TS-P1 and CR-043P tended to have a slightly lower area under the concentration time curve (AUC)The newly developed TS-P1 composition seemed to display similar curcumin systemic exposure except for a higher plasma concentration than the CR-033P composition. Further, only a few significant differences were found between CR-043P and CR-033P.

Objective: To evaluate the effects of the eight-week consumption of Theracurmin® on liver function, fatigue, and sleep. Methods: This was a randomized, double-blind, placebo-controlled, parallel-comparison study involving 68 healthy Japanese adults. Subjects were allocated into either the active (Theracurmin®) or placebo group ( n = 34 each) using a random number generator. Subjects consumed two capsules per day of either the active or placebo food for eight weeks. The primary outcome was the serum alanine aminotransferase (ALT) levels at eight weeks, whereas the secondary outcomes were the biomarkers of liver function, comparison of the percentages of improvement in liver function based on the decision criteria, OSA sleep inventory MA version (OSA-MA), and visual analog scale of fatigue. Results: Each group included 33 subjects in the full analysis set. ALT levels in the per protocol set analysis, except for subjects drinking quantities of alcohol that increase the risk of lifestyle-related disease onset, showed a significant decrease in ALT compared to the placebo group ( P < 0.05). The subjective symptom in the fatigue recovery factor of OSA-MA was significantly improved through the intervention ( P < 0.05). The fatigue recovery effect of Theracurmin® was prominent in the subjects aged ≤ 45 years, the age group defined by the Ministry of Health, Labour and Welfare as middle-aged and older persons in the Act on Stabilization of Employment of Elderly. No adverse event was observed. Conclusions: These results suggest that the consumption of Theracurmin® or eight weeks improved liver function and fatigue recovery at awakening in healthy Japanese adults. Trial registration: UMIN-CTR: UMIN000039319. Foundation: Theravalues Corporation Keywords: highly bioavailable curcumin, liver function, alanine aminotransferase (ALT), OSA sleep inventory MA version, fatigue recovery

We have developed an automatic bolt supply and tightening robot for an automatic segment assembly system that can support work in small-diameter tunnels. The segments are hex-head types, and the prototype handles segments with an inside diameter of 4.8 meters. The automatic bolt supply and tightening robot is separate from the erector used for positioning of the segment, which makes possible a compact segment gripper suitable for small-diameter tunnels. The bolt tightening robot consists of bolt tighteners that tighten bolts using AC servo motors, and a positioner that uses hydraulic servos. All bolts for the segment can be supplied automatically with higli precision, and tightening torques is controllable. The bolt supply robot employs an pneumatic actuator. Bolts are equipped with the bolt cartridges in sets made up of all the bolts required by an entire ring, and a set is automatically supplied to the tightening robot for each segment. Bolt supply is performed in parallel with segment supply, which contributes to overall work efficiency.

5-Hydroxyuracil derivatives were treated with stable Wittig reagents to give the corresponding 5-alkyluracil derivatives such as 5-methoxycarbonylmethyl-uridine and 5-carbamoylmethyluridine.